Peptide InjectionsAI
High evidence

Dulaglutide

Peptide therapy: benefits, side effects, cost and protocols

Dulaglutide, sold as Trulicity, is a once-weekly GLP-1 receptor agonist for type 2 diabetes treatment. It is also approved for reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or risk factors.

ByChris Riley(CFA)|Updated

Sources: FDA / PubMed / ClinicalTrials.gov View

FDA status
FDA-approved drug
Evidence
Strong Evidence

Who Dulaglutide is usually considered for

  • Blood sugar regulation
  • Cardiovascular risk reduction
  • Once-weekly dosing
  • Weight management support
  • Phase 4

How Dulaglutide works

Long-acting GLP-1 receptor agonist that mimics incretin hormones to regulate appetite and blood sugar with a weekly dosing schedule.

Key studies

1,383 papers on PubMed

  1. 01

    Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

  2. 02

    Nicholls SJ, Bhatt DL, Buse JB et al

    Am Heart J / Am Heart J / Phase 3

    SURPASS-CVOT design comparing tirzepatide vs dulaglutide on cardiovascular outcomes (recruitment complete, ongoing).

  3. 03

    SURPASS-CVOT design comparing tirzepatide vs dulaglutide on cardiovascular outcomes (recruitment complete, ongoing)

  4. 04

    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

  5. 05

    Nicholls SJ, Pavo I, Bhatt DL et al

    N Engl J Med / Phase 3

  6. 06

    Tirzepatide was noninferior to dulaglutide for cardiovascular outcomes (HR 0.92, p=0.003 for noninferiority)

  7. 07

    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

  8. 08

    Gerstein HC, Colhoun HM, Dagenais GR et al

    Lancet / Phase 3

  9. 09

    Dulaglutide reduced major adverse cardiovascular events vs placebo (HR 0.88, p=0.026)

  10. 10

    Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Dulaglutide questions

What is DULAGLUTIDE?

Dulaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes management. Marketed as Trulicity by Eli Lilly, it offers convenient weekly dosing and has shown cardiovascular risk reduction benefits.

How does DULAGLUTIDE work?

Long-acting GLP-1 receptor agonist that mimics incretin hormones to regulate appetite and blood sugar with a weekly dosing schedule.

Is DULAGLUTIDE legal to buy?

DULAGLUTIDE requires a prescription from a licensed healthcare provider. It is legal to purchase with a valid prescription from authorized pharmacies.

Where can I buy DULAGLUTIDE?

DULAGLUTIDE is available by prescription through compounding pharmacies and telehealth providers. Browse our verified provider directory to find trusted sources.

What category does DULAGLUTIDE belong to?

DULAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of DULAGLUTIDE?

DULAGLUTIDE has been studied for: Blood sugar regulation, Cardiovascular risk reduction, Once-weekly dosing, Weight management support. Once-weekly GLP-1 agonist; primarily for diabetes management. Marketed as Trulicity.

Dulaglutide in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Dulaglutide?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz